ES2175404T3 - Derivados de carbolina. - Google Patents

Derivados de carbolina.

Info

Publication number
ES2175404T3
ES2175404T3 ES97922960T ES97922960T ES2175404T3 ES 2175404 T3 ES2175404 T3 ES 2175404T3 ES 97922960 T ES97922960 T ES 97922960T ES 97922960 T ES97922960 T ES 97922960T ES 2175404 T3 ES2175404 T3 ES 2175404T3
Authority
ES
Spain
Prior art keywords
carboline derivatives
specific
those
cgmp
cyclical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97922960T
Other languages
English (en)
Inventor
Agnes Bombrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609820.7A external-priority patent/GB9609820D0/en
Priority claimed from GBGB9609777.9A external-priority patent/GB9609777D0/en
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of ES2175404T3 publication Critical patent/ES2175404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LOS DERIVADOS DE CARBOLINA DE FORMULA (I) SON INHIBIDORES POTENTES Y SELECTIVOS DE FOSFODIESTERASAS ESPECIFICAS AL 3'',5'' MONOFOSFATO DE GUANOSINA CICLICO (PDE ESPECIFICA AL CGMP) Y SON UTILES EN UNA AMPLIA VARIEDAD DE AREAS TERAPEUTICAS EN LAS QUE SE PIENSA ES CONVENIENTE TAL INHIBICION, INCLUIDO EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES.
ES97922960T 1996-05-10 1997-05-05 Derivados de carbolina. Expired - Lifetime ES2175404T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609820.7A GB9609820D0 (en) 1996-05-10 1996-05-10 Chemical compounds
GBGB9609777.9A GB9609777D0 (en) 1996-05-10 1996-05-10 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2175404T3 true ES2175404T3 (es) 2002-11-16

Family

ID=26309303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97922960T Expired - Lifetime ES2175404T3 (es) 1996-05-10 1997-05-05 Derivados de carbolina.

Country Status (26)

Country Link
US (2) US6117881A (es)
EP (1) EP0912567B1 (es)
JP (1) JP3418405B2 (es)
KR (1) KR20000010918A (es)
CN (1) CN1067071C (es)
AP (1) AP9801365A0 (es)
AT (1) ATE215950T1 (es)
AU (1) AU711885B2 (es)
BG (1) BG102879A (es)
BR (1) BR9709230A (es)
CA (1) CA2253948C (es)
CZ (1) CZ358598A3 (es)
DE (1) DE69711882T2 (es)
EA (1) EA199800907A1 (es)
EE (1) EE9800390A (es)
ES (1) ES2175404T3 (es)
HU (1) HUP9901478A3 (es)
IL (1) IL126951A0 (es)
IS (1) IS4864A (es)
NO (1) NO985222L (es)
OA (1) OA10920A (es)
PL (1) PL329875A1 (es)
SK (1) SK154498A3 (es)
TR (1) TR199802282T2 (es)
WO (1) WO1997043287A1 (es)
YU (1) YU49898A (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709230A (pt) * 1996-05-10 1999-08-10 Icos Corp Composto
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19837069C1 (de) * 1998-08-17 2000-01-05 Bayer Ag Substituierte Zimtsäuren und Zimtsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von substituierten Indanoncarbonsäureestern
CA2339630C (en) * 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
ES2213004T3 (es) 1999-03-24 2004-08-16 Harbor Branch Oceanographic Institution, Inc. Usos antiinflamatorios de manzaminas.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
MXPA00003997A (es) 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
MXPA02012470A (es) * 2000-06-23 2004-01-26 Lilly Icos Llc Inhibidores de fosfodiesterasa especificos para gmp ciclico.
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
MXPA03007140A (es) 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.
ATE346067T1 (de) * 2001-02-12 2006-12-15 Lilly Icos Llc Carbolinderivate
JP4216606B2 (ja) * 2001-04-25 2009-01-28 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
CA2445460A1 (en) 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
DE60213798T2 (de) 2001-06-21 2007-08-16 Lilly Icos Llc, Wilmington Carbolinderivate als pdev inhibitoren
MXPA04004370A (es) 2001-11-09 2004-08-11 Schering Corp Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
IL162602A0 (en) 2001-12-20 2005-11-20 Applied Research Systems Pyrrolidine derivatives as prostaglandin modulators
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
BRPI0508814B8 (pt) 2004-03-15 2021-05-25 Ptc Therapeutics Inc derivados de carbolina, bem como uso dos mesmos e composição farmacêutica
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
CN1972916B (zh) * 2004-05-26 2013-03-27 卫材R&D管理有限公司 肉桂酰胺类化合物
EP1757591A4 (en) 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
PL1829874T3 (pl) 2004-12-22 2014-07-31 Ono Pharmaceutical Co Tricykliczny związek i jego zastosowanie
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
CA2628047A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamide derivative
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
KR20100016580A (ko) * 2007-05-16 2010-02-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 원폿 제조 방법
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101925607A (zh) * 2008-01-28 2010-12-22 卫材R&D管理有限公司 结晶性的肉桂酰胺化合物或其盐
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150297601A1 (en) 2012-10-05 2015-10-22 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CA2999503A1 (en) 2015-09-23 2017-03-30 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
US12569493B2 (en) 2020-03-24 2026-03-10 Cyrano Therapeutics Inc. Treatment of chemosensory dysfunction from a coronavirus infection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (es) * 1982-07-24 1984-10-31 Pfizer
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
FI892362A7 (fi) * 1988-06-01 1989-12-02 Eisai Co Ltd Buteeni- tai propeenihappojohdannainen
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
BR9709230A (pt) * 1996-05-10 1999-08-10 Icos Corp Composto
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives

Also Published As

Publication number Publication date
KR20000010918A (ko) 2000-02-25
HUP9901478A2 (hu) 1999-08-30
EP0912567B1 (en) 2002-04-10
CA2253948C (en) 2005-07-26
PL329875A1 (en) 1999-04-12
US6306870B1 (en) 2001-10-23
AU711885B2 (en) 1999-10-21
IL126951A0 (en) 1999-09-22
HUP9901478A3 (en) 1999-11-29
CN1067071C (zh) 2001-06-13
AU2891097A (en) 1997-12-05
BR9709230A (pt) 1999-08-10
EP0912567A1 (en) 1999-05-06
JP3418405B2 (ja) 2003-06-23
ATE215950T1 (de) 2002-04-15
EA199800907A1 (ru) 1999-04-29
DE69711882T2 (de) 2002-10-31
NO985222L (no) 1999-01-11
DE69711882D1 (en) 2002-05-16
TR199802282T2 (xx) 1999-03-22
JP2000513717A (ja) 2000-10-17
US6117881A (en) 2000-09-12
YU49898A (sh) 2000-03-21
OA10920A (en) 2003-02-21
SK154498A3 (en) 2000-01-18
NO985222D0 (no) 1998-11-09
EE9800390A (et) 1999-06-15
AP9801365A0 (en) 1998-12-31
WO1997043287A1 (en) 1997-11-20
IS4864A (is) 1998-10-13
CA2253948A1 (en) 1997-11-20
BG102879A (en) 1999-09-30
CZ358598A3 (cs) 1999-03-17
CN1218471A (zh) 1999-06-02

Similar Documents

Publication Publication Date Title
ES2175404T3 (es) Derivados de carbolina.
ES2176471T3 (es) Inhibidores ciclicos gmp-especificos de la fosfodiesterasa.
LU91017I2 (fr) Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci
ES2131116T3 (es) Analogos de nucleotidos enantiomericos antirretrovirales.
HUP0004211A2 (hu) PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
DE69622031D1 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
ES2182234T3 (es) Inhibidores de metaloproteasa.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
MY106406A (en) Acryloyl substituted pyrrole derivatives.
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2098790T3 (es) Derivados de 1,2,3,5,6,7,8,8a-octahidro-5,5,8a-trimetil-(8abeta)-6-isoquinoleinamina, su procedimiento de preparacion y su empleo en terapeutica.
DE60318826D1 (de) Alkoxypyridinderivate
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
PT94957A (pt) Processo para preparacao de composicoes farmaceuticas para tratamento da hipertrofia e hiperplasia cardiais e vasculares compreendendo um inibidor do enzima de conversao da angiotensina
ES2182090T3 (es) Nuevos derivados de pirrol.
DE60226970D1 (de) Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
IL138288A0 (en) Process for the production of purine derivatives and intermediates thereof
UY26329A1 (es) Antagonistas de los receptores de vitronectina
ES2154408T3 (es) Inhibidores de serina proteasa derivados de imidazo(1,5a)piridina.
BR9810335A (pt) Uso de inibidores de fosfolambano para aumentar o fluxo coronário
ES2125884T3 (es) Hexahidrobenzo(f)quinolinonas como inhibidores de la 5-alfa-reductasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 912567

Country of ref document: ES